drugset / Trial / NCT03149120
Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be associated with an improvement in progression free survival (PFS) at 6 months
Timeline
- Start
- 2017-08
- Primary completion
- 2017-08-17
- Completion
- 2022-06
Outcome
Outcome not reported
Stopped (Enrollment): “No patient enrolled as new similar study will be in system within 3 months”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |